Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

China Pharma Holdings (CPHI) Equity Average (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Equity Average for 15 consecutive years, with $7.4 million as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Equity Average rose 6.02% year-over-year to $7.4 million, compared with a TTM value of $7.4 million through Sep 2025, up 6.02%, and an annual FY2024 reading of $7.6 million, up 29.44% over the prior year.
  • Equity Average was $7.4 million for Q3 2025 at China Pharma Holdings, up from $6.7 million in the prior quarter.
  • Across five years, Equity Average topped out at $7.9 million in Q1 2024 and bottomed at $3.4 million in Q3 2022.
  • Average Equity Average over 5 years is $6.2 million, with a median of $6.7 million recorded in 2025.
  • The sharpest move saw Equity Average crashed 48.73% in 2022, then soared 90.39% in 2023.
  • Year by year, Equity Average stood at $6.4 million in 2021, then plummeted by 44.65% to $3.6 million in 2022, then skyrocketed by 90.39% to $6.8 million in 2023, then rose by 5.24% to $7.1 million in 2024, then increased by 3.5% to $7.4 million in 2025.
  • Business Quant data shows Equity Average for CPHI at $7.4 million in Q3 2025, $6.7 million in Q2 2025, and $7.4 million in Q1 2025.